Form 4: OS Therapies CFO Granted 200,000 Stock Options

OS Therapies Inc.'s Chief Financial Officer, Christopher P. Acevedo, was granted options to purchase 200,000 shares of common stock at an exercise price of $1.8.

Summary

• Christopher P. Acevedo, Chief Financial Officer of OS Therapies Inc. (OSTX), reported changes in beneficial ownership.
• Acevedo was granted options to purchase 200,000 shares of the issuer's common stock.
• The exercise price for these options is $1.8 per share.
• The options were granted on October 21, 2025.
• These options will vest in full on the one-year anniversary of the grant date, October 21, 2026, provided Acevedo remains an employee.
• The options expire on October 21, 2035.
• Following this transaction, Acevedo directly owns 109,375 shares of common stock and 200,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is generally viewed as a positive for aligning management incentives with shareholder interests, though it's a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of 200,000 stock options to the Chief Financial Officer aligns management's long-term interests with shareholder value creation.
• The vesting schedule encourages retention of key executive talent for at least one year.

Risks

• Potential future dilution if the stock options are exercised, increasing the number of outstanding shares.
• The value of the options is dependent on the future stock price exceeding the $1.8 exercise price.

Future Outlook

The granted stock options are subject to a one-year vesting period, requiring Christopher P. Acevedo's continued employment with OS Therapies Inc. until October 21, 2026, to fully realize the award.

Industry Context

This filing reflects a standard practice of executive compensation within the biotechnology or pharmaceutical industry, where stock options are frequently used to incentivize and retain key management personnel, aligning their financial interests with the long-term performance of the company.

Stakeholder Impact

• Shareholders: Potential for increased alignment of CFO's interests with shareholder value; potential future dilution if options are exercised.
• Employees: Standard executive compensation practice, may signal stability in key management roles.

Next Steps

• Vesting of the 200,000 stock options on October 21, 2026, contingent on continued employment.
• Potential exercise of options by Christopher P. Acevedo between the vesting date and the expiration date.

Key Dates

Keywords

OS Therapies Inc, OSTX, Christopher P. Acevedo, Chief Financial Officer, Stock Options, Beneficial Ownership, Insider Transaction, Executive Compensation, Equity Grant, Form 4